In vitro characterization of the activity of PF-05095808, a novel biological agent for hepatitis C virus therapy

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1364-1375

  Lavender, Helen ^a   Brady, Kevin ^a   Burden, Frances ^a   Delpuech Adams, Oona ^a   Denise, Hubert ^a   Palmer, Amy ^a   Perkins, Hannah ^a   Savic, Boris ^a   Scott, Sarah ^a   Smith Burchnell, Caroline ^a   Troke, Phil ^a   Wright, J Fraser ^b   Suhy, David ^c   Corbaua, Romu ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b Tacere Therapeutics Inc   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIVIRUS AGENT; LENTIVIRUS VECTOR; PF 05095808; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REPLICON; RNA INTERFERENCE; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME;

BASE SEQUENCE; BIOLOGICAL ASSAY; CAPSID; CELL LINE, TUMOR; DEPENDOVIRUS; DRUG RESISTANCE, VIRAL; GENE THERAPY; GENES, REPORTER; GENETIC VECTORS; GENOME, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LUCIFERASES; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; REPLICON; RNA CLEAVAGE; RNA INTERFERENCE; RNA, SMALL INTERFERING; VIRUS REPLICATION;

EID: 84857153485     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05357-11     Document Type: Article

References (45)

1. Bernstein E, Caudy A, Hammond S, Hannon G. 2001. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409:363-366. (Pubitemid 32151243)
2. Blight KJ, Kolykhalov AA, Rice CM. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974.
3. Boden D, Pusch O, Lee F, Tucker L, Ramratnam B. 2003. Human immunodeficiency virus type 1 escape from RNA interference. J. Virol. 77:11531-11535. (Pubitemid 37271651)
4. Davidoff AM, et al. 2005. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol. Ther. 11:875- 888.
5. DeVincenzo J, et al. 2010. A randomized, double-blind, placebocontrolled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc. Natl. Acad. Sci. U. S. A. 107:8800-8805.
6. Domitrovich AM, Kunkel GR. 2003. Multiple, dispersed human U6 small nuclear RNA genes with varied transcriptional efficiencies. Nucleic Acids Res. 31:2344-2352. (Pubitemid 37442102)
7. Dong X, et al. 2010. Establishment of an AAV reverse infection-based array. PLoS One 5:e13479.
8. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T. 2001. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 20:6877- 6888.
9. Fire A, et al. 1998. Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature 391:806-811. (Pubitemid 28099681)
10. Gao GP, et al. 2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U. S. A. 99:11854-11859.
11. Gao X, et al. 2011. Prevalence and trend of hepatitis C virus infectionamong blood donors in Chinese mainland: a systematic review and metaanalysis. BMC Infect. Dis. 11:88.
12. Ge D, et al. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401.
13. Gitlin L, Stone JK, Andino R. 2005. Poliovirus escape from RNA interference: short interfering RNA-target recognition and implications for therapeutic approaches. J. Virol. 79:1027-1035.
14. González-Carmona MA, et al. 2011. 2010. Inhibition of hepatitis C virus gene expression by adenoviral vectors encoding antisense RNA in vitro and in vivo. J. Hepatol. 55:19-28.
15. Grimm D, et al. 2006. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441:537-541. (Pubitemid 44050158)
16. Henry SD, et al. 2006. Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes. Mol. Ther. 14:485-493. (Pubitemid 44296093)
17. Hoofnagle JH, Seeff LB. 2006. Peginterferon and ribavirin for chronic hepatitis C. N. Engl. J. Med. 355:2444-2451. (Pubitemid 44903748)
18. Howe AY, et al. 2008. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. Antimicrob. Agents Chemother. 52:3327-3338.
19. Kato T, et al. 2006. Cell culture and infection system for hepatitis C virus. Nat. Protoc. 1:2334-2339.
20. Kim DH, et al. 2005. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat. Biotechnol. 23:222-226.
21. Krönke J, et al. 2004. Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs. J. Virol. 78:3436 -3446.
22. Kuiken C, Hraber P, Thurmond J, Yusim K. 2008. The hepatitis C sequence database in Los Alamos. Nucleic Acids Res. 36:D512-D516. (Pubitemid 351149775)
23. Liang Y, et al. 2009. Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology 137:1448-1458.
24. Lohmann V, Hoffmann S, Herian U, Penin F, Bartenschlager R. 2003. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J. Virol. 77:3007-3019. (Pubitemid 36228086)
25. Lok AD, et al. 2011. Quadruple therapy with BMS-790052, BMS-650032 and peg-Ifn/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders. J. Hepatol. 54(Suppl 1):S536.
26. McCarty DM. 2008. Self-complementary AAV Vectors; Advances and Applications. Mol. Ther. 16:1648 -1656.
27. McIntyre GJ, Groneman JL, Yu YH, Tran A, Applegate TL. 2011. Multiple shRNA combinations for near-complete coverage of all HIV-1 strains. AIDS Res. Ther. 8:1.
28. Morrissey DV, et al. 2005. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 41:1349-1356. (Pubitemid 40770288)
29. Nakai H, et al. 2001. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J. Virol. 75:6969-6976. (Pubitemid 32641584)
30. Petrocca F, Lieberman J. 2011. Promise and challenge of RNA interference-based therapy for cancer. Clin. Oncol. 29:747-754.
31. Prabhu R, et al. 2005. Small interfering RNA effectively inhibits protein expression and negative strand RNA synthesis from a full-length hepatitis C virus clone. J. Med. Virol. 76:511-519. (Pubitemid 40943261)
32. Rao DD, Vorhies JS, Senzer N, Nemunaitis J. 2009. siRNA vs. shRNA: similarities and differences. Adv. Drug Deliv Rev. 61:746-759.
33. Sakamoto N, et al. 2008. Inhibition of hepatitis C virus infection and expression in vitro and in vivo by recombinant adenovirus expressing short hairpin RNA. J. Gastroenterol. Hepatol. 23:1437-1447.
34. Stiffler JD, et al. 2009. Focal distribution of hepatitis C virus RNA in infected livers. PLoS One 4:e6661.
35. Suzuki H, Tamai N, Habu Y, Chang MO, Takaku H. 2008. Suppression of hepatitis C virus replication by baculovirus vector-mediated shorthairpin RNA expression. FEBS Lett. 582:3085-3089.
36. Thomas DL, et al. 2009. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798-801.
37. Vaishnaw AK, et al. 2010. A status report on RNAi therapeutics. Silence 1:14.
38. Vermeulen A, et al. 2005. The contributions of dsRNA structure to Dicer specificity and efficiency. RNA 11:674-682. (Pubitemid 40594334)
39. Vona G, et al. 2004. Intrahepatic hepatitis C virus RNA quantification in microdissected hepatocytes. J. Hepatol. 40:682-688. (Pubitemid 38367792)
40. Wang L, et al. 2010. Systematic evaluation of AAV vectors for liver directed gene transfer in murine models. Mol. Ther. 18:118 -125.
41. Wilson JA, Richardson CD. 2006. Future promise of siRNA and other nucleic acid based therapeutics for the treatment of chronic HCV. Infect. Disord. Drug Targets 6:43-56. (Pubitemid 43796635)
42. Wright JF, et al. 2005. Identification of factors that contribute to recombinant AAV2 particle aggregation and method to prevent its occurrence during vector purification and formulation. Mol. Ther. 12:171-178. (Pubitemid 40862369)
43. Wu Z, et al. 2008. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol. Ther. 16:280-289. (Pubitemid 351168036)
44. Yang X, Haurigot V, Zhou S, Luo G, Couto LB. 2010. Inhibition of hepatitis C virus replication using adeno-associated virus vector delivery of an exogenous anti-hepatitis C virus microRNA cluster. Hepatology 52:1877-1887.
45. Zhang J, et al. 2005. Inhibition of hepatitis C virus replication by pol III-directed overexpression of RNA decoys corresponding to stem-loop structures in the NS5B coding region Virology 342:276.